Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Read more about Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Read more about CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues.
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Read more about First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Read more about The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Read more about Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Read more about Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Read more about Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Read more about Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Read more about Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Read more about An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
